Zusammenfassung
Die Strategie einer aktiven Überwachung („active surveillance“) des lokalisierten Prostatakarzinoms mit selektiver, verzögerter Intervention könnte grundsätzlich für viele Patienten eine Alternative zur sofortigen kurativen Therapie (radikale Prostatektomie oder Strahlentherapie) darstellen. Im Gegensatz zur aus Patientensicht immer stärker werdenden Forderung nach dieser Option stehen jedoch die noch relativ spärlichen prospektiven Daten zu einer solchen Strategie. Es ist immer noch unklar, wie die Patienten selektiert werden sollen und welche Kriterien für einen Abbruch der Überwachung und die Empfehlung einer Intervention angewendet werden sollen. Bevor die Option der „active surveillance“ eine wirkliche Alternative zur kurativen Therapie darstellt, müssen aktuell initiierte prospektive Studien beendet sein. So lange sollten Patienten für diese Therapiemöglichkeit eher strenger selektiert und engmaschiger überwacht werden.
Abstract
The treatment strategy of “active surveillance” with selective but delayed intervention for patients with organ-confined prostate cancers could be an attractive alternative to the known curative options of radical prostatectomy or radiotherapy. The increasing demand of patients and doctors, however, stands in contrast to a rather sparse data basis for this approach in prospective studies. It remains unclear which patients should be selected for the approach and at which point the strategy of “active surveillance” should be stopped and converted to active treatment interventions. As long as these important data are missing from the currently running prospective trials, the treatment strategy of “active surveillance” should be recommended with caution and for strictly selected patients only. The follow-up regimens with biopsy and PSA should consist of frequent visits and close observations of these parameters.
Literatur
Albertsen PC, Hanley JA, Gleason DF, Barry MJ (1998) Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280: 975–980
Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293(17): 2095–2101
Albertsen PC, Hanley JA, Penson DF et al. (2007) 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol 177(3): 932–936
Becker N (2003) Epidemiological aspects of cancer screening in Germany. J Cancer Res Clin Oncol 129(12): 691–702
Bill-Axelson A, Holmberg L, Ruutu M et al. (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 12;352(19): 1977–184
Breslow N, Chan CW, Dhom G et al. (1977) Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer. 20(5): 680–688
Carter HB, Ferrucci L, Kettermann A et al. (2006) Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98(21): 1521–1527
Carter CA, Donahue T, Sun L et al. (2003) Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol 21(21): 4001–4008
Cuzick J, Fisher G, Kattan MW et al. (2006) Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 95(9): 1186–1194
D’Amico AV, Whittington R, Malkowicz SB et al. (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11): 969–974
D’Amico AV, Cote K, Loffredo M et al. (2003) Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era. J Urol 170(6 Pt 2): S42–46; discussion S46–47
D’Amico AV, Chen MH, Roehl KA, Catalona WJ. (2004) Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351(2): 125–135
Epstein JI, Chan DW, Sokoll LJ et al. (1998) Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160(6 Pt 2): 2407–2411
Evans HS, Moller H (2003) Recent trends in prostate cancer incidence and mortality in southeast England. Eur Urol 43(4): 337–341
Fenton JJ, Cai Y, Weiss NS et al. (2007) Delivery of cancer screening: how important is the preventive health examination? Arch Intern Med 167(6): 580–585
Holmberg L, Bill-Axelson A, Helgesen F et al. (2002) A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347(11): 781–789
Johansson J-E, Andrén O, Andersson S-O et al. (2004) Natural history of Eearly, localized prostate cancer. JAMA 291: 2713–2719
Khan MA, Carter HB, Epstein JI et al. (2003) Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol 170: 2274–2278
Klotz L (2005) Active surveillance for prostate cancer: for whom? J Clin Oncol 23(32): 8165–8169
Koch K (2003) Information on early cancer diagnosis: what do the patients want? Med Klin 98(7): 400–403
Ochiai T, Shimeno H, Mishima K et al. (2007)The relationship between serum prostate specific antigen level and tumor volume persists in the current era. J Urol 177(3): 903–906
Ochiai A, Trpkov K, Yilmaz A et al. (2007)Validation of a prediction model for low volume/low grade cancer: application in selecting patients for active surveillance. J Urol 177(3): 907–910
Parker C, Muston D, Melia J et al. (2006) A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 94(10): 1361–1368
Sakr WA, Grignon DJ, Crissman JD et al. (1994) High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20–69: an autopsy study of 249 cases. In Vivo 8(3): 439–443
Steineck G, Helgesen F, Adolfsson J (2002) Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 347(11): 790–796
Sved PD, Gomez P, Manoharan M et al. (2004) Limitations of biopsy Gleason grade: implications for counseling patients with biopsy Gleason score 6 prostate cancer. J Urol 172(1): 98–102
de Vries SH, Postma R, Raaijmakers R et al. (2007) Overall and disease-specific survival of patients with screen-detected prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam. Eur Urol 51(2): 366–374
Warlick C, Trock BJ, Landis P et al. (2006) Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 98(5): 355–357
Zhu H, Roehl KA, Antenor JA, Catalona WJ (2005) Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis. Urology 66(3): 547–551
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Czeloth, K., Albers, P. „Active surveillance“ des lokalisierten Prostatakarzinoms. Onkologe 13, 691–700 (2007). https://doi.org/10.1007/s00761-007-1229-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00761-007-1229-5